Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
A
298380
vs
K
KOSPI 200
Over the past 12 months, ABL Bio Inc has underperformed KOSPI 200, delivering a return of -53% compared to KOSPI 200's +53% growth.
Stocks Performance
298380 vs KOSPI 200
Performance Gap
298380 vs KOSPI 200
Performance By Year
298380 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ABL Bio Inc
Glance View
ABL Bio is a South Korean biotechnology company that discovers and develops antibody-based medicines. Its main work is creating biologic drug candidates, especially bispecific antibodies and antibody platforms designed to improve how cancer and neurological drugs reach their targets. It does not sell everyday consumer products; it sells drug development programs and licensing rights around its science. The company makes money in the biopharma value chain by partnering with larger drugmakers, licensing out its antibody technology, and advancing some of its own drug candidates through research and clinical development. Its main customers and partners are pharmaceutical companies that want access to new antibody platforms, as well as the eventual patients and hospitals that would use its medicines if they are approved. What sets ABL Bio apart is its role as a technology and drug-discovery company rather than a mass manufacturer. It focuses on building tools that help other therapies work better, such as antibodies that can bind two targets at once or help drugs cross the blood-brain barrier. That makes it a platform-driven biotech whose value depends on the strength of its science, patent position, and partnering deals.